Atrial Fibrillation (AF)AF-CARDNCT07437456
AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)
An observational study of Atrial Fibrillation (AF), run by Eurasian Association of Therapists at 1 site in Russia.
Trial summary
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no… Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Atrial Fibrillation (AF)
- How many people
- 3,500 participants
- Where
- 1 siteRussia
- Study dates
- 1 Jul 2026to Jan 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Study population: Anonymized male and female patients aged 18 to 64 years suffering from atrial fibrillation confirmed by a specialist, with a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
Who may be able to join
- Male or female patients aged 18 to 64 years at the time of data registration;
- Presence of a specialist-confirmed diagnosis of atrial fibrillation;
- CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
- Non-inclusion criteria for the retrospective part:
- Age under 18 years;
- Age over 64 years;
Show all 23Show fewer
- CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women;
- Inability to undergo screening examination and follow-up;
- Organ or tissue transplantation less than 5 years prior to study enrollment;
- Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment;
- Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake.
- Prospective Part
- Male or female patients aged 18 to 64 years at the time of data registration;
- Presence of a specialist-confirmed diagnosis of atrial fibrillation;
- CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening.
- Non-inclusion criteria for the prospective part:
- Age under 18 years;
- Age over 64 years;
- CHA₂DS₂-VASc score greater than 2 for men and greater than 3 for women;
- Inability to undergo screening examination and follow-up;
- Organ or tissue transplantation less than 5 years prior to study enrollment;
- Open heart surgery (coronary artery bypass grafting, valve replacement, reconstructive aortic surgery) within 6 months prior to study enrollment;
- Established diagnosis of dementia of any severity and/or established diagnosis of moderate or severe encephalopathy, as well as other conditions precluding independent regular medication intake.
Who cannot join
- Patient withdrawal of consent for further participation in the study;
- Identification of factors precluding further patient participation in the study (at the physician's discretion).
Trial locations and contacts
1 site in 1 country.
About this study
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
Read the detailed description
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
The registry comprises both a retrospective and a prospective component. Patient enrollment in the retrospective part will be conducted through the review of medical records of individuals who were followed up for atrial fibrillation at the participating centers during the preceding three years. For inclusion in the prospective part, screening of all patients meeting the predefined inclusion and non-inclusion criteria will be performed during routine outpatient and inpatient care, followed by prospective follow-up over a three-year period.
Data derived from the retrospective and prospective phases of the registry will enable an epidemiological assessment of the demographic and clinical characteristics, outcomes, and therapeutic approaches employed in real-world clinical practice among patients with atrial fibrillation. These findings may provide important insights to advance the understanding of diagnostic and management strategies, and to inform efforts aimed at optimizing healthcare delivery within this patient cohort.
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- Atrial Fibrillation, Anticoagulant Therapy, Thromboembolic Complications
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Retrospective branch | The retrospective cohort will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the study inclusion criteria at the time of that visit. | |
| Prospective branch | All patients aged 18 to 64 years at the time of data registration, with a specialist-confirmed diagnosis of atrial fibrillation and a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative incidence of thromboembolic complications
To assess the cumulative incidence of atrial fibrillation-related thromboembolic complications (including transient ischaemic attack, ischaemic stroke, and systemic thromboembolism) in patients with initially low risk over the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 month
Secondary outcomes (13)
Number of Atrial Fibrillation Paroxysms During the Follow-up Period
To assess the number of documented episodes (paroxysms) of atrial fibrillation in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 month
Rate of Hospitalizations Due to Atrial Fibrillation Paroxysm During the Follow-up Period
To assess the number of hospitalizations associated with atrial fibrillation paroxysm in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Rate of Catheter Ablation of Pulmonary Vein Ostia During the Follow-up Period
To assess the number of catheter ablation procedures of the pulmonary vein ostia performed in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Complications of Anticoagulant Therapy
To assess the incidence of major bleeding (including hemorrhagic stroke), moderate bleeding, and minor bleeding in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) to Oral Anticoagulants During the Follow-up Period
To assess the proportion of patients who switched from antiplatelet therapy (acetylsalicylic acid, clopidogrel, ticagrelor) to oral anticoagulants at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Oral Anticoagulants to Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) During the Follow-up Period
To assess the proportion of patients who switched from oral anticoagulants to antiplatelet therapy (acetylsalicylic acid, clopidogrel, ticagrelor) at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Warfarin to Direct Oral Anticoagulants During the Follow-up Period
To assess the proportion of patients who switched from warfarin to direct oral anticoagulants at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Direct Oral Anticoagulants to Warfarin During the Follow-up Period
To assess the proportion of patients who switched from direct oral anticoagulants to warfarin at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Hospitalization for Cardiovascular Disease
To assess the rate of hospitalizations related to cardiovascular disease in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
All-Cause Hospitalization
To assess the rate of hospitalizations for any cause in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
All-Cause Mortality
To assess the rate of death from any cause in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Cardiovascular Mortality
To assess the rate of death from cardiovascular causes in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Death from Hemorrhagic Complications, Including Hemorrhagic Stroke
To assess the rate of death related to hemorrhagic complications (including hemorrhagic stroke) in patients at each visit throughout the follow-up period.
Measured: 6, 12, 18, 24, 30, 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 Jul 2026
- Primary completionSep 2028 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 3,500 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Eurasian Association of Therapists
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alexander Arutyunov, professor, Study chair, Eurasian Association of Therapists
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07437456
- Sponsor's protocol ID
- AF-CARD
- Acronym
- AF-CARD
- Status last verified
- Sep 2026
- First submitted
- 22 Feb 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)
- ClinicalTrials.gov ID
- NCT07437456
- Acronym / sponsor ID
- AF-CARD / AF-CARD
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- Atrial Fibrillation, Anticoagulant Therapy, Thromboembolic Complications
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 3,500 participants (estimated)
- Lead sponsor
- Eurasian Association of TherapistsUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
Detailed description
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
The registry comprises both a retrospective and a prospective component. Patient enrollment in the retrospective part will be conducted through the review of medical records of individuals who were followed up for atrial fibrillation at the participating centers during the preceding three years. For inclusion in the prospective part, screening of all patients meeting the predefined inclusion and non-inclusion criteria will be performed during routine outpatient and inpatient care, followed by prospective follow-up over a three-year period.
Data derived from the retrospective and prospective phases of the registry will enable an epidemiological assessment of the demographic and clinical characteristics, outcomes, and therapeutic approaches employed in real-world clinical practice among patients with atrial fibrillation. These findings may provide important insights to advance the understanding of diagnostic and management strategies, and to inform efforts aimed at optimizing healthcare delivery within this patient cohort.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Retrospective branch | – | –The retrospective cohort will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the study inclusion criteria at the time of that visit. |
| Prospective branch | – | –All patients aged 18 to 64 years at the time of data registration, with a specialist-confirmed diagnosis of atrial fibrillation and a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening. |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Anonymized male and female patients aged 18 to 64 years suffering from atrial fibrillation confirmed by a specialist, with a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
Key inclusion criteria (23 listed)
- Male or female patients aged 18 to 64 years at the time of data registration;
- Presence of a specialist-confirmed diagnosis of atrial fibrillation;
- CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
- Age under 18 years;
- Age over 64 years;
Key exclusion criteria (2 listed)
- Patient withdrawal of consent for further participation in the study;
- Identification of factors precluding further patient participation in the study (at the physician's discretion).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cumulative incidence of thromboembolic complications
Time frame: 6, 12, 18, 24, 30, 36 month
To assess the cumulative incidence of atrial fibrillation-related thromboembolic complications (including transient ischaemic attack, ischaemic stroke, and systemic thromboembolism) in patients with initially low risk over the follow-up period.
13 secondary outcomes
Number of Atrial Fibrillation Paroxysms During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 month
Rate of Hospitalizations Due to Atrial Fibrillation Paroxysm During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Rate of Catheter Ablation of Pulmonary Vein Ostia During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Complications of Anticoagulant Therapy
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) to Oral Anticoagulants During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Oral Anticoagulants to Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Warfarin to Direct Oral Anticoagulants During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Direct Oral Anticoagulants to Warfarin During the Follow-up Period
Time frame: 6, 12, 18, 24, 30, 36 months
Hospitalization for Cardiovascular Disease
Time frame: 6, 12, 18, 24, 30, 36 months
All-Cause Hospitalization
Time frame: 6, 12, 18, 24, 30, 36 months
All-Cause Mortality
Time frame: 6, 12, 18, 24, 30, 36 months
Cardiovascular Mortality
Time frame: 6, 12, 18, 24, 30, 36 months
Death from Hemorrhagic Complications, Including Hemorrhagic Stroke
Time frame: 6, 12, 18, 24, 30, 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexander Arutyunov, professor study chair
Eurasian Association of Therapists
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation (AF), run by Eurasian Association of Therapists at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative incidence of thromboembolic complications (time frame: 6, 12, 18, 24, 30, 36 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.